Patents by Inventor Bert Klebl

Bert Klebl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS
    Publication number: 20240294522
    Abstract: The present invention relates to certain 3-substituted 1 H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease or medical condition mediated through GRK5 selected from heart disease, inflammatory and immunological disease, metabolic disease and cancer.
    Type: Application
    Filed: June 15, 2022
    Publication date: September 5, 2024
    Inventors: Jianmin Zhang, Julian Engel, Matthias Baumann, Peter Nussbaumer, Bert Klebl, Carsten Schultz-Fademrecht
  • COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION
    Publication number: 20240252454
    Abstract: The present invention relates to a composition comprising at least one inhibitor of mitochondrial transcription (IMT) and at least one anti-cancer drug. Furthermore, the present invention is directed to compositions for use as a medicament and to compositions for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 1, 2024
    Inventors: Tim BERGBREDE, Raffaella DI LUCREZIA, Anke UNGER, Axel CHOIDAS, Bert KLEBL, Peter NUSSBAUMER, Sascha MENNINGER, Peter HABENBERGER, Gunther ZISCHINSKY, Uwe KOCH, Peter SCHRÖDER, Pavla JESTRABOVÁ, Lenka PALOVÁ-JELÍNKOVÁ, Klára DÁNOVÁ, Maria FALKENBERG-GUSTAFSSON, Laleh ARABANIAN, Claes GUSTAFSSON, Nils-Göran LARSSON, Lars PALMQVIST
  • 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER
    Publication number: 20220370440
    Abstract: The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.
    Type: Application
    Filed: August 23, 2019
    Publication date: November 24, 2022
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Peter Nussbaumer, Carsten Degenhart, Matthias Baumann
  • Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
    Patent number: 11111238
    Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: September 7, 2021
    Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschften e.V., SOTIO a.s.
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
  • COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
    Publication number: 20200291011
    Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 17, 2020
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
  • 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
    Patent number: 10703735
    Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 7, 2020
    Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
  • 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
    Publication number: 20200031794
    Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Application
    Filed: July 23, 2019
    Publication date: January 30, 2020
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
  • Pharmaceutically active disubstituted pyridine derivatives
    Patent number: 9242937
    Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: January 26, 2016
    Assignees: Bayer Intellectual Property GmbH, LEAD DISCOVERY CENTER GMBH
    Inventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
  • CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA
    Publication number: 20150329537
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: November 19, 2015
    Applicants: LEADDISCOVERY CENTER GMBH, MAX-PLANCK GESELLSCHAFTZUR FORDERUNG DER WIS SENSCHAFTEN E.V
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Pharmaceutically active compounds as Axl inhibitors
    Patent number: 8999982
    Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: April 7, 2015
    Assignees: Lead Discovery Center GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Axel Choidas, Uwe Koch, Jan Eickhoff, Alexander Wolf, Axel Ullrich
  • CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA
    Publication number: 20140303167
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: October 9, 2014
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Pharmaceutically Active Disubstituted Pyridine Derivatives
    Publication number: 20140296304
    Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 2, 2014
    Applicants: LEAD DISCOVERY CENTER GMBH, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
  • SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS
    Publication number: 20140287454
    Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.
    Type: Application
    Filed: August 22, 2012
    Publication date: September 25, 2014
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS
    Publication number: 20140018365
    Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 26, 2011
    Publication date: January 16, 2014
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V., LEAD DISCOVERY CENTER GMBH
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Axel Choidas, Uwe Koch, Jan Eickhoff, Alexander Wolf, Axel Ullrich
  • 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20130338147
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 19, 2013
    Applicant: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
    Patent number: 8507498
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES
    Publication number: 20130079345
    Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 20, 2011
    Publication date: March 28, 2013
    Applicants: BAYER INTELLECTUAL PROPERTY GMBH, LEAD DISCOVERY CENTER GMBH
    Inventors: Jan Eickhoff, Peter Nussbaumer, Gerd Ruhter, Carsten Schultz-Fademrecht, Ulrich Lucking, Axel Choidas, Bert Klebl
  • Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
    Patent number: 8084457
    Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: December 27, 2011
    Assignees: Lead Discovery Center GmbH, Bayer Pharma AG
    Inventors: Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltán Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Müller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
  • 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20110306602
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: April 24, 2008
    Publication date: December 15, 2011
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Lutz Zeitlmann, Anke Mueller, Martin Augustin, Michael A. Pleiss, Gabriele Stumm, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • NOVEL C. ELEGANS P21-ACTIVATED KINASE (PAK) GENE AND ASSOCIATED LOSS-OF-FUNCTION PHENOTYPES THAT FACILITATE SCREENING FOR SMALL MOLECULE MODULATORS OF PAK ACTIVITY IN THE NEMATODE, CAENORHABDITIS ELEGANS
    Publication number: 20080213798
    Abstract: The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling.
    Type: Application
    Filed: October 12, 2007
    Publication date: September 4, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Kaj GRANDIEN, Jonathan ROTHBLATT, Paola CONCARI, Isabelle QUELO, Bert KLEBL